BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) ("BioHarvest" or "the Company") has announced the first multimedia campaign for VINIA™ in the USA, Phase 1. The company is scaling up its US marketing in line with a 2022 growth plan that aims for significant growth in sales orders following commercial entry in 2021.

"We are delighted to launch our first integrated marketing campaign aimed at expanding our loyal customer base here in the USA," said CEO Ilan Sobel, in New York for the launch. "Bringing our new 20 Ton production facility online was integral to scaling global VINIA™ supply, so this marketing launch is testament to the entire VINIA™ team's coordinated dedication to making it happen."

The initial phase will include TV and online advertising with a special focus on Christian programming, which includes TBN (Trinity Broadcasting Network, the world's largest religious-based television network). As part of the sponsorship agreement with TBN, Sobel will appear on the network's flagship shows hosted by Eric Metaxas and Mike Huckabee, with all content to be supported by advertising and educational online content.

New 60-second VINIA™ commercials were created specifically for the TBN campaign, to start Aug 15, 2022 (View example here)

The campaign underscores VINIA's concept of "Cellular Nutrition" and the benefits of increased blood flow, bringing in Sobel and members of his own family.

"I am inspired every day to hear from our customer community on ways that VINIA™ is improving their health," Sobel said. "We measure our success by our ability to make significant positive impact to people's lives, and as such our products' efficacy is proven not only in the clinical trials but also on a daily basis with VINIA's users."

See this link for a review of the impact on three generations of the Sobel family.

BioHarvest Sciences Inc. (CSE: BHSC) is a fast-growing Biotech firm listed on the Canadian Securities Exchange. BioHarvest has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants, at industrial scale, without the need to grow the plant itself. This technology is economical, ensures consistency, and avoids the negative environmental impacts associated with traditional agriculture. BioHarvest is currently focused on nutraceuticals and the medicinal cannabis markets. Visit: www.bioharvest.com.

BioHarvest Sciences Inc. Ilan Sobel, Chief Executive Officer

For further information, please contact: Dave Ryan, VP Investor Relations & Director Phone: 1 (604) 622-1186 Email: dave@bioharvest.com

Twitter: https://twitter.com/bioharvestbhsc Facebook: https://www.facebook.com/BioHarvestSciences LinkedIn: https://www.linkedin.com/company/bioharvestsciences/ YouTube: https://www.youtube.com/channel/UCGRJWztmLoycsLFWqwXAzAw

Information set forth in this news release includes forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. There is no assurance that strong sales metrics experienced to date will result in future demand or that proposed additional marketing expenditures will result in increased sales. There is no assurance that the company will achieve significant growth in sales orders as this would require that the marketing campaign is successful which is subject to uncertainty, particularly the response of target audiences to the campaign. Markets for nutraceuticals are unpredictable and subject to changes in consumer tastes and trends as well as economic factors beyond our control. Delays and cost overruns may result in delays achieving our objectives obtaining market acceptance, and regulatory approvals for geographic expansion are subject to risk and cannot be guaranteed.

All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/134209

News Provided by Newsfile via QuoteMedia

BioHarvest Sciences (CSE:BHSC), a biotechnology innovator, is targeting the international market demand for natural products that provide consumers with functional health and wellness. This includes consumer products ranging from foods enriched with active ingredients like antioxidants to cleaner and more consistent cannabis products. BioHarvest Sciences has developed biofarming, a proprietary breakthrough patented technology, capable of naturally-producing the active ingredients of a plant without having to grow the plant itself. The company has already proven the technology in the rapidly growing nutraceuticals market focusing on dietary supplements and the functional food and beverage ingredients market. Products such as BioHavest Sciences’ VINIA®, which is based on red grapes, has clinically- proven functional benefits, has already positively impacted the lives of thousands of Israelis and is approved for sale in the US.

The global cannabis market is expected to reach US$66.3 billion by the end of 2025, according to a report by Grand View Research. A large portion of the growth has been driven by the adoption of cannabis in the pharmaceutical industry as new products have been developed to treat severe medical conditions such as cancer, Parkinsons, Alzheimers and arthritis. However, issues with consistent cannabis supply can affect the long-term growth of the industry as more countries initiate cannabis programs and legislative reforms, posing potential difficulties for licensed producers to provide enough high-quality products to meet the demand.

BioHarvest Sciences Inc. believes that its biofarming technology is the solution to the cannabis supply and consistency problem. The technology isolates the active ingredient cells from the cannabis plant before multiplying (growing) them in the biofarming process. The technology can do this without using any solvent extraction, genetic modification or synthetic molecular processing techniques. To facilitate its biofarming operation, BioHarvest Sciences Inc. has built a production facility that can produce approximately one ton of active cannabis ingredient powder (equivalent to the cannabis plant dried bud) per year in a 100-square-meter space. The company intends to increase its production to 10 tons per year by 2022.

As of September 2019, the company produced its first cannabis cells in suspension with a cannabinoid profile that was identical to the original cannabis plant without growing the plant. Following a B2B business model, BioHarvest Sciences Inc. intends to sell its active ingredients as a powder for repackaging and formulation to its clients. In addition, the company may License the technology in order to accelerate the industry adoption curve.

In December 2021, the company released the news that it has now grown a significant amount (10kg) of cannabis biomass, all grown in proprietary bioreactors and without growing the plant. Following a B2B business model, BioHarvest Sciences Inc. intends to sell its active ingredients as a powder for repackaging and formulation to its clients. In addition, the company may License the technology in order to accelerate the industry adoption curve.

BioHarvest Sciences has already demonstrated the feasibility and viability of the biofarming technology through its commercially available product called VINIA®. In 2021, BioHarvest recorded US$2.4 million worth of sales orders for VINIA®, a nearly sixfold increase over 2020. The growth is driven by a growing customer base in Israel, and a successful ecommerce launch of VINIA® in the USA. The projected revenue this year is between US$5 million to US7 million, which represents a significant growth of 2.5X-3.5X over 2021.

VINIA® is based on many studies which have demonstrated that moderate consumption of red wine every day is able to have a positive impact on one’s overall heart health as a result of wine’s rich polyphenol content, specifically resveratrol. One 400mg capsule of VINIA® contains the same amount of resveratrol contained in one full bottle of Red Wine without the sugar, calories or alcohol found in red wine. Consumers can currently purchase the powder through the VINIA.com website in a 400-milligram daily dose after BioHarvest made it possible to also make VINIA® available online in the United States, the world's largest market for nutraceutical supplements.

At present, BioHarvest is unstoppable in disrupting industries with unique products and solutions. After VINIA®'s immense sales success, the company has trademarked its proprietary non-GMO biotech platform technology called "Bio-Plant CELLicitation™," replacing "BioFarming".

In an interview, BioHarvest CEO Ilan Sobel talked about Bio-Plant CELLicitation™, a platform technology growing plant cells in industrial-scale bioreactors and eliciting specific molecules to produce unique botanical compounds with high human utility value. Accoridng to Sobel, the unique platform technology allows them to grow full-spectrum, non-GMO cannabis.

""We can play in so many different areas, not just nutraceuticals, not just the cannabinoid space, but in many other areas where we're able to bring the power of the plant to the people," Sobel said.

Dr. Rakib is a serial entrepreneur and seasoned executive. He brings extensive experience in multiple industries. Prior to BioHarvest Sciences, Dr. Rakib co-founded Terayon Communication Systems, led the company from inception as its CEO, and managed its growth from $2M to $380M in revenue. Terayon reached a $7B market capitalization in 2000 and was later on acquired by Motorola. Prior to that, Mr. Rakib was a director of engineering at Cadence design systems which acquired Helios S/W where he served as CTO. Dr. Rakib holds a Ph.D. in Mechanical Engineering and a Ph.D. in Applied Mathematics.

Ilan, brings extensive experience in General Management, International Sales & Marketing, Manufacturing & Operations and leadership expertise in building large-scale businesses and billion- dollar brands. For the past 6 years, Ilan served as COO and transitioned to Chief Commercial Officer of Weissbeerger where he played a major leadership role in building a disruptive BIG Data, IOT & Software Company servicing major Beverage players which was recently purchased by ABInBev. Previously, Ilan served an 18-year stint as an International Employee of The Coca-Cola Company, where he played a pivotal role in key senior leadership positions generating significant revenue and profit growth and improving brand health trends across diverse global markets including the United States, China, South East and West Asia and South Africa.

With a Ph.D in Biotechnology and 20+ years of relevant experience, leading substantial research and development programs in both pharma and biotech, Dr. Hagay has lead the development and implementation of BioHarvest’s technology platform since inception. She previously worked in various leadership positions at BTG corporation which was acquired by FERRING Pharmaceuticals. Dr. Hagay specializes in genetic engineering, molecular biology, tissue culture, monoclonal antibodies and clinical trials. She is the author and co-author of several peer-reviewed – published in scientific papers.

David Ryan has extensive experience in investment and public markets. For the past 20+ years, he has been part of in bringing multiple initial public offerings to market. He has helped raise both equity and debt financings for numerous public companies in both primary and secondary financings as well as served on the board of public companies and in various roles.

Mr. Popper was the co-founder and President of MedReleaf Corp., which was acquired in 2018 for $2.5 billion USD. Prior to its acquisition, MedReleaf was one of the largest and most reputable vertically integrated medical Cannabis producers in the world. Mr. Popper brings over 15 years of international partnerships, entrepreneurial ventures, disruptive industry, large-scale project development, engineering and investment experience. He holds a B.Sc. in Civil Engineering, a M.Sc. in Environmental Fluid Mechanics from Stanford University, and an MBA from the Recanati School of Business.

Dr. Azachi brings 20 years of experience in biochemistry, genetic engineering, tissue culture, molecular biology, and clinical & pre-clinical trials. Prior to BioHarvest, He served as technology Director at HealOr Ltd, a Biopharmaceutical company developing topical therapeutics. Prior, he led product development at the research and development department of Colbar LifeScience, a Johnson & Johnson Company. Dr. Azachi holds a Ph.D in microbiology from the Hebrew University of Jerusalem and a Post-Doc in Molecular Biology of the cell from Weizmann Institute of Science.

Michal Sapir brings 30+ years of experience in the medical device, pharma and biotechnology industries. She has previously served as Senior Director of Project Management at ColBar LifeScience Ltd., a Johnson & Johnson Company. She actively participated in FDA meetings in order to define regulatory pathways, FDA inspections and ISO Audits. She has broad experience in clinical and animal studies; and had formerly served as Affiliate Quality Coordinator & Senior Clinical Research Administrator in Eli Lilly (1995-2000). Michal Holds a Master of Science in Biochemistry.

Brady brings to the advisory board 30 years of experience as an integrative and nutritional medicine practitioner and over 25 years in health sciences academia. He is a licensed naturopathic medical physician in Connecticut and Vermont, is board certified in functional medicine and clinical nutrition, and is a fellow of the American College of Nutrition. Dr. Brady has been the Chief Medical Officer of Designs for Health, Inc. and also currently serves as the Chief Medical Officer for Diagnostic Solutions Labs, LLC. He was the long-time Vice President for health sciences and Director of the Human Nutrition Institute and continues to serve as an associate professor of clinical sciences, at the University of Bridgeport in Connecticut. He has published multiple peer-reviewed scientific papers and textbooks related to chronic pain, autoimmunity, and functional gastroenterology. Furthermore. Dr. Brady appeared on the plenary speaking panels of some of the largest and most prestigious conferences in the field including; IFM, ACAM, A4M, ACN, IHS, AANP, AIHM, and many more.

Mr. Tsur is the co-founder of Kamada Ltd, a public company listed on both the NASDAQ and Tel-Aviv Stock Exchange. He served as its Chief Executive Officer and on its Board of directors since the Company’s inception in 1990. He currently serves as Deputy Chairman of the Board.

He also serves as the Chairman of Kanabo Group Plc, a company listed on the London Stock Exchange, which focuses on distributing Cannabis-derived products for medical patients and non-THC products for CBD consumers.

Steven currently sits on the Board of Directors of two life science companies, one not for profit, and is a member of the University of Maryland's Bioengineering Department Advisory Board. He provides strategy and implementation advice to several organizations on various topics from commercial efforts through operations, business development, product development, portfolio planning to the establishment of international operations. Previously Steve was Head of Biologicals at Cipla Ltd., CEO of Cipla BioTec, President of Glycominds Ltd, EVP of Adamas Pharmaceuticals Inc., CEO of GeneOs Ltd, CEO at DNA Sciences, and was a division President of Monsanto. Steven also worked with McKinsey & Co., and Proctor & Gamble Corporation.

Hadfield brings 40 years of scientific experience to the Canadian-Israeli biotech firm, which has developed and patented a plant bio-cell technology, called BioFarming, capable of growing the active and beneficial plant based ingredients at industrial scale, without the need to grow the plant itself.

INN does not provide investment advice and the information on this profile should not be considered a recommendation to buy or sell any security. INN does not endorse or recommend the business, products, services or securities of any company profiled.

The information contained here is for information purposes only and is not to be construed as an offer or solicitation for the sale or purchase of securities. Readers should conduct their own research for all information publicly available concerning the company. Prior to making any investment decision, it is recommended that readers consult directly with BioHarvest Sciences Inc. and seek advice from a qualified investment advisor.

BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) ("BioHarvest" or "the Company") ") is pleased to announce that its common shares are now trading on the OTCQB® Venture Market under the ticker symbol "CNVCF".

"Admission to the OTCQB® market is an important step to increase US investor access to BioHarvest Sciences, and it provides US investors an additional level of transparency as we expand both our investor base and our customer base in North America." Stated CEO Ilan Sobel. "We will continue to work on expanding our global visibility to investors to match the commercial entry of our products into new markets."

The BioHarvest Sciences Executive team holds regular online meetings to maintain close ties with the US investment community. All interested media and investors are invited to contact info@bioharvest.com for information on the Company's next interactive event. For more detail on 2022 progress, the July 7, Q2 Shareholder Update focuses on the Company's scale-up plans in the US for its VINIA product, and the market entry strategy for the Company's cannabis products. The recording of that event is available here: https://bioharvest.com/investors/

The OTCQB® Venture Market is for early-stage and developing U.S. and international companies. To be eligible, companies must be current in their financial reporting and undergo an annual verification and management certification process. The OTCQB® quality standards provide a strong baseline of transparency, as well as the technology and regulation to improve the information and trading experience for investors.

Investors can find current financial disclosure and quotes for the company on https://www.otcmarkets.com/stock/CNVCF.

BioHarvest Sciences will continue to trade on the Canadian Securities Exchange (CSE) as "BHSC" and on Frankfurt as "8MV".

BioHarvest Sciences Inc. (CSE: BHSC) is a fast-growing Biotech firm listed on the Canadian Securities Exchange. BioHarvest has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants, at industrial scale, without the need to grow the plant itself. This technology is economical, ensures consistency, and avoids the negative environmental impacts associated with traditional agriculture. BioHarvest is currently focused on nutraceuticals and the medicinal cannabis markets. Visit: www.bioharvest.com.

BioHarvest Sciences Inc. Ilan Sobel, Chief Executive Officer

For further information, please contact:

Dave Ryan, VP Investor Relations & Director  Phone: 1 (604) 622-1186 Email: dave@bioharvest.com

Information set forth in this news release includes forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. There is no assurance that strong sales metrics experienced to date will result in future demand or that proposed additional marketing expenditures will result in increased sales. Markets for nutraceuticals are unpredictable and subject to changes in consumer tastes and trends as well as economic factors beyond our control. Delays and cost overruns may result in delays achieving our objectives obtaining market acceptance, and regulatory approvals for geographic expansion are subject to risk and cannot be guaranteed. Projected sales of BioHarvest products will require the Company to obtain production and/or export licensing which cannot be assured.

All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/131117

News Provided by Newsfile via QuoteMedia

BioHarvest Sciences Inc. (CSE: BHSC) (OTC PINK: CNVCF) (FSE: 8MV) ("BioHarvest" or "the Company") today announced that Batory Foods (Batory) has placed a purchase order for 1,000 kg of VINIA®, to be delivered by end of December 2022. Batory Foods ("Batory"), a leading food ingredients distributor in the USA, is one of the top three companies in the nutraceutical and food and beverage ingredient segments of the market. Batory is the exclusive B2B distributor of BioHarvest's Nutraceuticals and expected Hemp based Cannabis products in the US.

In addition to the significant size of this purchase order, it also carries more favorable financial terms for BioHarvest in reflection of the higher B2B wholesale price of VINIA® in the market and reflects the willingness of end customers to pay higher pricing for VINIA® when utilizing VINIA® as a key ingredient in their respective products. The adoption of VINIA® by the US market is evidenced by the sales growth and projections described in the Company's July 5th, 2022, news release.

"Teaming up with BioHarvest Sciences from the get-go was a strategic diversification of our product portfolio to include on-trend and high-end functional ingredients" stated Vince Pinneri, President of Batory Foods. "We have identified major end customers who can appreciate the value of the scientific and clinical based Nutraceuticals from BioHarvest and are convinced of the prospects of integrating these into their offerings to consumers".

VINIA® is now being designed and tested in multiple products by major US brands covering a wide gamut of applications such as coffee, tea, yoghurt, nutrition bars, and nutritional beverages.

Ilan Sobel, CEO of BHSC, commented "We made a sound decision in September 2020 to partner with Batory. This partnership reflected their vote of confidence in the scientifically and clinically proven advantages of BHSC's technology and portfolio of unique products. Batory has been a great partner to help us drive the required disruption in the nutraceutical ingredients industry. This latest purchase order is just the beginning of what is a mutually beneficial long-term relationship and we look forward to partnering with Batory on our journey for VINIA® to be included as a strategic ingredient in major brands in the nutraceutical, and food & beverage industries. "

BioHarvest invites all interested investors and media to the Q2 BioHarvest Shareholder Update at 2PM EST July 7th, 2022. The online meeting will be hosted by CEO Ilan Sobel and will feature a live Q&A session. Free registration to the event is available here: Q2 2022 BioHarvest Sciences Inc. Shareholder Update | BioHarvest Sciences (livestorm.co)

BioHarvest Sciences Inc. (CSE: BHSC) is a fast-growing Biotech firm listed on the Canadian Securities Exchange. BioHarvest has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants, at industrial scale, without the need to grow the plant itself. This technology is economical, ensures consistency, and avoids the negative environmental impacts associated with traditional agriculture. BioHarvest is currently focused on nutraceuticals and the medicinal cannabis markets. Visit: www.bioharvest.com.

BioHarvest Sciences Inc. Ilan Sobel, Chief Executive Officer

For further information, please contact: Dave Ryan, VP Investor Relations & Director  Phone: 1 (604) 622-1186 Email: dave@bioharvest.com

Information set forth in this news release includes forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. There is no assurance that strong sales metrics experienced to date will result in future demand or that proposed additional marketing expenditures will result in increased sales. Markets for nutraceuticals are unpredictable and subject to changes in consumer tastes and trends as well as economic factors beyond our control. Delays and cost overruns may result in delays achieving our objectives obtaining market acceptance, and regulatory approvals for geographic expansion is subject to risk and cannot be guaranteed. There is no assurance that our products will be integrated into products by major US brands as this will depend on successful testing by them of our products and any products which may integrate our products and the assessment of the potential market acceptance of such products which is uncertain. There is no assurance that the Company sales revenue for 2022 will reach USD 5 to 7 million and there is no assurance that the Company cash flow breaking point will be achieved in 2023. There is no assurance of commercial availability of our Cannabis product in 2022 or that the Company achieves the conversion of the two tons VINIA® facility to Cannabis production in 2022. These things are subject to construction and approval delays and uncertainties that may be beyond the control of BioHarvest. Projected sales of Cannabis will require the Company to obtain production and/or export licensing which cannot be assured.

All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/130224

News Provided by Newsfile via QuoteMedia

BioHarvest Sciences Inc. (CSE: BHSC) (OTC PINK: CNVCF) (FSE: 8MV) ("BioHarvest" or "the Company") today announced Q2 2022 sales orders of its flagship VINIA® product reached a record high of USD 947k, representing 99% growth compared to the same quarter of last year and 24% growth compared to Q1 2022.

BioHarvest also had a strong quarter in R&D execution, highlighted by a May 12th announcement unveiling the profile of its unique Cannabis biomass composition produced in large-scale industrial bioreactors. BioHarvest also applied for a Cannabis production license in Israel. This quarter also saw the transition to the new 20Tons/year VINIA® facility in Yavneh, Israel which will enable the further scaling of the VINIA® business in the US in H2, 2022 and will deliver significant cost reductions over the next 12 months.

"Our strong Q2 results demonstrate our consistent growth and represent a validation of our major assumptions and performance so far," said CEO Ilan Sobel. "BioHarvest's strategy of growth remains well intact and its performance on all fronts validates its leadership in plant-based bio-technology."

Q2 sales orders in the US reached USD 376k (representing 460% growth over Q2 2021 and 21% growth over Q1 2022). The US sales metrics were extremely healthy and demonstrate steady improvement. For example, customer Average Revenue per Unit for the last 6 months was USD 229 compared to over the last 12 months at USD 198. The percentage of 3 month or greater subscriptions increased from 56% of the subscription mix in Q1, 2021 to 76% for Q2, 2022. In addition, VINIA® continues to achieve a best-in class verified customer rating of 4.8 out of 5 with over 700 verified reviews, demonstrating a high level of customer satisfaction. These strong results were delivered through the 2nd quarter as the Company continued to manage US VINIA® sales orders in line with production capacity constraints, which will be further alleviated early in the 2nd half of 2022 with the increased manufacturing scale of the new 20 ton/year facility, enabling increased inventory to flow through to the US market.

The Israeli market continued to demonstrate increased consumer adoption of VINIA® and delivered USD 571k (39% growth over Q1 2021 and 26% growth from Q1 2022). Total Customers in Israel grew at a record 51% in Q2 2022 over Q1 2022. It is also noteworthy that June saw the highest ever "average spend per order" of USD 203.

The second half of the 2022 marketing plan includes the addition of influencer endorsements, customer referral programs and affiliate programs as well as a focused approach addressing key lucrative market segments such as the Christian evangelical market. Given the above marketing activity, B2B pipeline opportunities and the release of the VINIA® manufacturing bottle neck, the Company is reiterating its 2022 sales orders guidance of USD 5M-7M representing a 2.5-3.5X growth over 2021.

"I look back with satisfaction at our achievements in H1 2022 and look forward with enthusiasm to H2 2022. The accomplishments of H1 2022 give me the confidence in delivering strong results in H2 2022 and to continue to fuel our growth engines, as I have articulated consistently several times to the market and to our investors." Sobel said. "I am equally satisfied and enthusiastic for how the unique, highly differentiated composition of our Cannabis is opening the doors for the partnership discussions with Multi State Operators in the US."

BioHarvest invites all interested investors and media to the Q2 BioHarvest Shareholder Update at 2PM EST July 7th, 2022. The online meeting will be hosted by CEO Ilan Sobel and will feature a live Q&A session. Free registration to the event is available here:

https://app.livestorm.co/st-financial/q2-2022-bioharvest-sciences-shareholder-update?type=detailed

BioHarvest Sciences Inc. (CSE: BHSC) is a fast-growing Biotech firm listed on the Canadian Securities Exchange. BioHarvest has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants, at industrial scale, without the need to grow the plant itself. This technology is economical, ensures consistency, and avoids the negative environmental impacts associated with traditional agriculture. BioHarvest is currently focused on nutraceuticals and the medicinal cannabis markets. Visit: www.bioharvest.com.

BioHarvest Sciences Inc. Ilan Sobel, Chief Executive Officer

For further information, please contact: Dave Ryan, VP Investor Relations & Director  Phone: 1 (604) 622-1186 Email: dave@bioharvest.com

Information set forth in this news release includes forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. There is no assurance that strong sales metrics experienced to date will result in future demand or that proposed additional marketing expenditures will result in increased sales. Markets for nutraceuticals are unpredictable and subject to changes in consumer tastes and trends as well as economic factors beyond our control. Delays and cost overruns may result in delays achieving our objectives obtaining market acceptance, and regulatory approvals for geographic expansion are subject to risk and cannot be guaranteed. There is no assurance that the Company sales revenue for 2022 will reach USD 5 to 7 million and there is no assurance that the Company cash flow breaking point will be achieved in 2023. There is no assurance of commercial availability of our Cannabis product in 2022 or that the Company achieves the conversion of the two tons VINIA® facility to Cannabis production in 2022. These things are subject to construction and approval delays and uncertainties that may be beyond the control of BioHarvest. Projected sales of Cannabis will require the Company to obtain production and/or export licensing which cannot be assured.

All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/129989

News Provided by Newsfile via QuoteMedia

BioHarvest Sciences Inc. (CSE: BHSC) ("BioHarvest" or the "Company") today announced that effective immediately, Gavriel Lambert will be serving on its Board of Advisors. Gavriel brings 27 years of experience in global investment banking and will complement BioHarvest's highly competent Board of Advisors.

Ilan Sobel, CEO of BioHarvest, said: "Gavriel's extensive experience in banking comes at an important junction of the company's evolution as it seeks new partnerships with several US and international entities that would accelerate the market reach of BHSC's products and technology. Not only will he help introduce us to the right strategic partners but he will also assist us in the process of achieving the best possible agreements. Furthermore, his capital markets experience will offer us valuable advice as a public company."

Gavriel Lambert said: "I strongly believe in the power of the Bio-Plant CELLicitation™ technology that BioHarvest brought to the world. This proprietary technology is set to make a significant impact in the life science-based businesses and as such is attractive to a large array of US and international companies covering multiple multi billion dollars' verticals including Cannabis, Food, Nutraceuticals, Biotech and Pharma. The Cannabis vertical in particular is very promising given the fundamental difference BioHarvest can make in this industry. I look forward to working with my fellow advisors and senior management."

As of May 22, Gavriel has been appointed Head of Consumer Retail Group, EMEA (Europe, Middle East and Africa) and Co-Head of Global Retail for Jefferies Group.

Gavriel Lambert BioHarvest Sciences Board of Advisors To view an enhanced version of this graphic, please visit: https://orders.newsfilecorp.com/files/6168/129651_aba01b0a54f34b31_001full.jpg

Prior to this new appointment and from 2016, Gavriel headed the EMEA Consumer Retail Group for Barclays Plc. He led a team of global professionals with primary coverage responsibility, client development, new business solicitation, transaction origination and execution for a broad range of retail, consumer and e-commerce clients. He has been involved in several dozens of significant M&A and financing transactions.

Prior to joining Barclays in 2013, his extensive career (that started in 1995) included holding senior investment banking positions at Solomon Smith Barney, J.P. Morgan and UBS Securities.

Gavriel holds a Master's degree (MBA) in finance from the Columbia Business School and a BSc Honors in Psychology from the London School of Economics.

BioHarvest Sciences Inc. (CSE: BHSC) is a fast-growing Biotech firm listed on the Canadian Securities Exchange. BioHarvest has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants, at industrial scale, without the need to grow the plant itself. This technology is economical, ensures consistency, and avoids the negative environmental impacts associated with traditional agriculture. BioHarvest is currently focused on nutraceuticals and the medicinal cannabis markets. Visit:www.bioharvest.com.

Ilan Sobel, Chief Executive Officer

For further information, please contact:

Dave Ryan, VP Investor Relations & Director Phone: 1 (604) 622-1186 Email: dave@bioharvest.com

Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. There is no assurance that we will achieve our objective of making our products available in multiple markets. There is no assurance that the Company will be successful in expanding its technology to broader medical applications or conduct clinical trials to validate the efficacy of the Company's products for new forms of medical treatments. There is no assurance that we will achieve our objective of being a leading supplier of Cannabis, whether in North America or other global markets. Delays and cost overruns may result in delays achieving our objectives obtaining market acceptance and regulatory approvals for geographic expansion are subject to risk and cannot be guaranteed. Projected sales of Cannabis will require the company to obtain production and/or export licensing which cannot be assured.

All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/129651

News Provided by Newsfile via QuoteMedia

 BioHarvest Sciences Inc. (CSE: BHSC) ("BioHarvest" or "the Company") invites its shareholders and the general public to join a Live Video Conference ("Webinar") on Thursday, July 7, 2022, at 2:00 PM Eastern Standard Time (11:00 AM Pacific Standard Time).

BioHarvest Sciences CEO Ilan Sobel will host the event, which will include coverage of Q2 sales results and a detailed progress update on the 2022 Growth Priorities, with specific focus on the VINIA scale-up progress in the USA and on the Company's Cannabis market entry strategy into North America.

" We have reached the midpoint of 2022, which will be remembered as a transformative year in BioHarvest Science's growth," states CEO Ilan Sobel, adding "This year we have already made key additions to our leadership team and reached major scientific milestones - I am very excited to discuss our progress on the VINIA USA scale-up, to provide a high level update on strategic partnership discussions with key players in the North American Cannabis landscape, and to share my thoughts with our Bioharvest shareholder partners on how our disruptive platform technology will reshape the future of the Cannabis industry in North America. "

The presentation will be approximately 45 minutes, followed by a live question and answer session. All shareholders, media, and interested investors are welcome to join. All registrants will be emailed a recording of the session. Any questions regarding the event can be sent to justin@bioharvest.com.

Register for free at: Q2 2022 BioHarvest Sciences Inc. Shareholder Update | BioHarvest Sciences (livestorm.co)

BioHarvest Sciences Inc. (CSE: BHSC) is a fast-growing Biotech firm listed on the Canadian Securities Exchange. BioHarvest has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants, at industrial scale, without the need to grow the plant itself. This technology is economical, ensures consistency, and avoids the negative environmental impacts associated with traditional agriculture. BioHarvest is currently focused on nutraceuticals and the medicinal cannabis markets. Visit:www.bioharvest.com.

BioHarvest Sciences Inc. Ilan Sobel, Chief Executive Officer

For further information, please contact: Dave Ryan, VP Investor Relations & Director Phone: 1 (604) 622-1186 Email: dave@bioharvest.com

Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. There is no assurance that we will achieve our objective of making our products available in multiple markets. There is no assurance that the Company will be successful in expanding its technology to broader medical applications or conduct clinical trials to validate the efficacy of the Company's products for new forms of medical treatments. There is no assurance that we will achieve our objective of being a leading supplier of Cannabis, whether in North America or other global markets. Delays and cost overruns may result in delays achieving our objectives obtaining market acceptance and regulatory approvals for geographic expansion are subject to risk and cannot be guaranteed. Projected sales of Cannabis will require the company to obtain production and/or export licensing which cannot be assured.

All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/128834

News Provided by Newsfile via QuoteMedia

Naturally Splendid Enterprises Ltd.("Naturally Splendid", "NSE" or "the Company") (FRANKFURT:50N) (TSX-V:NSP) (OTC:NSPDF) is pleased to announce that Sysco Canada has now listed the Company's PlanteinTM products nationally

Sysco is listing five (5) PlanteinTM plant-based entrees across Canada in multiple Sysco Distribution outlets. PlanteinTM products listed nationally at Sysco are PlanteinTM Nuggets; Crumbed Tenders; Sweet Chili Tenders; Garlic Kiev; and Crispy Burger. As a global leader in selling, marketing, and distributing food products, Sysco services restaurants, healthcare, educational facilities, lodging establishments and as well as a host of other customers around the world. Sysco Canada operates 16 Distribution Centres across Canada with an estimated 450 sales representatives servicing clients coast to coast.

This national listing is a direct result of Sysco's comprehensive due diligence process. PlanteinTM products will be available to all Sysco customers, including restaurants, healthcare facilities, schools, universities, hotels, lodging establishments, and other food service operators. Being strategically listed nationally allows Sysco customers from coast to coast the ability to order PlanteinTM without delay.

"We are extremely pleased that our PlanteinTM products have been approved by Sysco for national distribution," said Naturally Splendid CEO Mr. Craig Goodwin. "Sysco is a world-class organization with an incredible reach across Canada and North America. We believe our PlanteinTMproducts have a very bright future in food service and are confident PlanteinTM will be well-received by Sysco's customers. This national listing allows us to expand PlanteinTM to a wider audience of potential customers and expand our reach into new markets."

About Naturally Splendid Enterprises Ltd.

Naturally Splendid is a plant-based food manufacturing and technology company that produces and distributes nutritious and delicious plant-based commodity products.

Founded in 2010, the Company operates a certified food manufacturing facility located just outside Vancouver, BC in Canada, focusing on producing an extensive range of plant-based entrees. Naturally Splendid has an exclusive 10-year manufacturing and distribution agreement for Canada with a division of Australia's largest plant-based food manufacturer, Flexitarian Foods Pty. Ltd.

In addition to producing the Company's own branded products, Naturally Splendid provides contract manufacturing services and private labelling for a variety of nutritional plant-based food products destined for multiple distribution channels.

The Company has established healthy, functional foods under brands such as Natera Sport, Natera Hemp Foods, CHII™, Elevate Me™ and Woods Wild Bar™. The Company launched PlanteinTM Plant-Based Foods, a line of delicious plant-based meat alternatives for the rapidly growing plant-based market segment.

Naturally Splendid has reached an agreement with Biologic to terminate the agreement with Plasm Pharmaceutical and is negotiating a compensation package for work done to date pursuing a potential treatment for Covid with the target drug Cavaltinib.

NSE has also developed proprietary technologies for the extraction of healthy omega 3 and 6 oils, as well as a protein concentrate from hemp.

On Behalf of the Board of Directors

Mr. J. Craig Goodwin President, Director

Naturally Splendid Enterprises Ltd. (NSP - TSX Venture; NSPDF - OTCQB; 50N Frankfurt) #108-19100 Airport Way Pitt Meadows, BC, V3Y 0E2 Office: (604) 570-0902 E-mail: info@naturallysplendid.com Website: www.naturallysplendid.com

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. Naturally Splendid cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond Naturally Splendid's control including, Naturally Splendid's ability to compete with large food and beverage companies; sales of any potential products developed will be profitable; sales of shelled hemp seed will continue at existing rates or increase; customers will complete on sales contracts; and the risk that any of the potential applications may not receive all required regulatory or legal approval. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, Naturally Splendid undertakes no obligation to publicly update or revise forward-looking information.

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

SOURCE:Naturally Splendid Enterprises Ltd.

News Provided by ACCESSWIRE via QuoteMedia

Bloom Health Partners Inc. (CSE: BLMH) (OTCQB: BLMHF) (FSE: D840) ("Bloom" or the "Company"), a leading provider of operational health and health technology, announces unaudited Fiscal Q2 2022 revenues of CAD $8.4M for the three months ended June 30th, 2022, bringing year-to-date revenues to CAD $24.9M for the first three quarters of Fiscal 2022.

Full results available at www.sedar.com.

"We're thrilled to announce our third quarter results," said Andrew Morton, CEO of Bloom. "Our Fiscal Q3 2022 revenue of CAD $8.4M and aggregate CAD $24.9M year to date has resulted in us all but reaching our revenue guidance for FY 2022 in three quarters. We're proud of our team's performance so far this year as we continue to transition Bloom into an innovative provider of employer health-tech solutions and services. Our end-to-end platform strategy of clinical, labs and data in workplace health is well received by clients, partners and investors."

(1) This is a non-IFRS measure. Refer to the section "Non-IFRS Financial Measures" for information on the calculation of this non-IFRS measures. (2) Refer to the section "Disclosure on Financial Guidance" for additional information.

We believe that providing certain non-IFRS financial measures provide users with important information regarding the operational performance of our business. The non-IFRS financial measures used by management do not have any standardized meaning prescribed by IFRS and therefore may not be comparable to similar measures presented by other issuers. Accordingly, these measures should not be considered as a substitute or alternative for IFRS measures as determined in accordance with IFRS. By considering these measures in combination with the comparable IFRS financial measures, we believe that users are provided a better overall understanding of our business and financial performance during the relevant period than if they considered the IFRS financial measures alone.

EBITDA is defined as earnings before interest, income taxes, depreciation, and amortization and is utilized by management to assess and evaluate the financial performance of its operations. Management believes that EBITDA improves comparability between periods by eliminating the impact of interest, income taxes, depreciation, and amortization.

Adjusted EBITDA excludes items that are not considered to be indicative of operational and financial trends either by nature or amount to provide a better overall understanding of the Company's underlying business performance. The most directly comparable GAAP measure to EBITDA and Adjusted EBITDA is net income before tax, calculated as follows:

The most directly comparable GAAP measure to EBITDA is net income before tax, calculated as follows:

Anticipated revenue figures and EBITDA are based on modelling and estimates developed by management and updated as of June 30, 2022. These estimates are based on our Fiscal Year 2021 results and year-to-date 2022 results, including market size, and assume only ongoing business, as well as marginal growth in fixed costs through Fiscal Year 2022. Readers are cautioned that actual results could differ materially from these estimates based on increases in operating costs, failure to maintain regulatory licensing, inability to execute on existing contracts with schools in Texas, failure to attract and retain qualified employees, or a reduction in customer demand.

About Bloom Health Partners Inc.

Bloom Health Partners Inc. (CSE: BLMH) (OTCQB: BLMHF) (FSE: D840) is a global platform for healthcare security, diagnostic testing and occupational health-tech. Our mission is to ensure that "unstoppable is possible" for businesses and their employees through innovative, customized healthcare models. Bloom offers a system for businesses and organizations that helps engage employees and creates strategies to manage health and safety. Our stable, scalable system is an integrated health-tech platform that securely manages data while delivering comprehensive workplace health and safety outcomes.

For more information: investors@bloomhealthpartners.com

On behalf of the board of directors,

Andrew Morton, Chief Executive Officer

This news release includes forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in the Company's forward-looking statements include the potential that milestones may not be satisfied, acquisitions may not achieve expected benefits, financing requirements, and the other risk factors described in the Company's filings with Canadian securities regulators on www.sedar.com. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/135425

News Provided by Newsfile via QuoteMedia

~Greenlane adds new Chief Operating Officer while also elevating existing executives~

Greenlane Renewables Inc. ("Greenlane") (TSX: GRN) (FSE: 52G) is pleased to announce that Alex Chassels has joined Greenlane in the newly created role of Chief Operating Officer. Additionally, the Company is announcing the promotions of Maura Lendon to Chief Legal Officer and Sandra Keyton to Chief Human Resources Officer.

Alex Chassels brings over 25 years of experience and a track record of executive leadership in business transformation and operations optimization in growth-oriented technology companies with innovative products and complex global supply chains. Through growing positions of responsibility and leadership with Creo, Kodak, and Alpha Technologies (an Enersys Company) he has developed a clear team-based approach to delivering the highest levels of customer satisfaction. Alex holds a BA in Philosophy (Magna Cum Laude) and Chemistry from the University of Arizona .

"The extraordinary growth in our business and strength of our balance sheet is presenting us with many new opportunities, and as a result we are rapidly building the Company, adding talented new team members and accelerating systemic and process enhancements," said Brad Douville , Chief Executive Officer. "I am excited to announce the expansion of our senior management team and the appointment of Alex Chassels as Chief Operating Officer. Alex will help us scale, transform and optimize our operations as we build on our strong reputation in the sector and further invest in the business to continue building Greenlane into a leading global biogas upgrading system provider."

"From our existing management team, I am also honored to announce the promotions of Maura Lendon to Chief Legal Officer and Sandra Keyton to Chief Human Resources Officer," added Douville. "Both Maura and Sandra have demonstrated solid leadership and made significant contributions during our recent phase of growth and will both play important roles going forward as we expect to continue building Greenlane's business and presence in the global RNG market."

Greenlane Renewables is a pioneer in the rapidly growing renewable natural gas (" RNG ") industry. As a leading global provider of biogas upgrading systems, we are helping to clean up two of the largest and most difficult-to-decarbonize sectors of the global energy system: the natural gas grid and the commercial transportation sector. Our systems produce clean, low-carbon and carbon-negative RNG from organic waste sources such as landfills, wastewater treatment plants, dairy farms, and food waste streams. To the company's knowledge, Greenlane is the only biogas upgrading company offering the three main technologies: waterwash, pressure swing adsorption, and membrane separation. Greenlane's business has been built on over 30 years of industry experience, patented and proprietary technology, over 100 hydrogen sulfide treatment systems sold, and over 135 biogas upgrading systems sold into 19 countries, including some of the largest RNG production facilities in the world. For further information, please visit www.greenlanerenewables. com .

FORWARD LOOKING INFORMATION – This news release contains "forward-looking information" within the meaning of applicable securities laws. All statements contained herein that are not historical in nature contain forward-looking information. Forward-looking information can be identified by words or phrases such as "may", "is expected", "likely", "should", "would", "plan", "anticipate", "intend", "potential", "proposed", "estimate", "believe" or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions "can", "may" or "will" happen. In particular, this news release contains forward looking information relating the role and impact of the expanded senior management team on the transformation and optimization of the Company's business as well as the Company's presence in the global RNG market. The forward-looking information contained herein is made as of the date of this press release and is based on assumptions management believed to be reasonable at the time such statements were made, including management's perceptions of future growth and expected future developments, as well as other considerations that are believed to be appropriate in the circumstances. While management considers these assumptions to be reasonable based on information currently available to management, there is no assurance that such expectations will prove to be correct. By their nature, forward-looking information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond the Company's control, could cause actual results to differ materially from the forward-looking information in this press release. Such factors include, without limitation, that the expanded senior management team does not deliver the transformation and optimization of the Company's business or impact the Company's presence in the global RNG market as anticipated and risks identified in the Company's annual information form and in other documents filed with Canadian securities regulatory authorities on the Company's SEDAR profile at www.sedar.com . Readers are cautioned not to put undue reliance on forward-looking information. Actual results may differ materially from those anticipated. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/August2022/31/c8726.html

News Provided by Canada Newswire via QuoteMedia

This release acts as a correction for the release posted on 8/29/2022 at 10:30 PM EDT from Naturally Splendid Enterprises Ltd. announcing its second quarter results for 2022 due to an error in comments stated

Naturally Splendid Enterprises Ltd. ("Naturally Splendid", "NSE" or "the Company") (FRANKFURT:50N)(TSXV:NSP)(OTC PINK:NSPDF) announces its unaudited financial results for the six months ended June 30, 2022. All amounts are in Canadian dollars and are prepared in accordance with International Financial Reporting Standards

Naturally Splendid CFO Mr. George Ragogna states, "We apologize for an error in the comments overview of our Financial results. The first sentence below referenced our Administrative expenses for the six months ending June 30, 2022, and for the comparative period. We regret any confusion and have corrected the first sentence in the statement below to reflect the net loss and comprehensive loss."

Naturally Splendid recorded a net loss and comprehensive loss of $1,714,438 for the six months ended June 30, 2022, compared to a net loss of $1,750,988 during the six months ended June 30, 2021. Gross profit margins decreased by 2.6% of sales in the six months ended June 30, 2021, compared to the six months ended June 30, 2021. The Company's sales decreased by approximately $312,000 from the comparative period. During the six-month period ending June 30, 2022, selling and distribution expenses decreased by approximately $16,500, largely due to facility costs.

Administrative expenses for the six months ended June 30, 2022, decreased in 2022 compared to 2021 by $87,500.The decrease was primarily due to management & consulting fees, bank charges and legal fees.

Naturally Splendid recorded sales of $157,314 during the six months ended June 30, 2022, compared to $470,039 for the six months ended June 30, 2021. During the six months ended June 30, 2022, the Company's sales decreased by approximately $313,000 from the comparative period. The Company had decreased sales in its private-label bars and bites business by approximately $85,000. Branded hemp products decreased by approximately $170,200 and its Natera Sport products decreased by approximately $73,000. Sales in new Plant-based products decreased by approximately $4,300.

The Cost of Sales during the six months ended June 30, 2022, was $136,186 compared to $394,812 in 2021. The Company's sales were from its new line of plant-based entrees, which maintain a higher gross margin. The Company continues to focus on its higher-margin products and new commercial opportunities with its plant-based entrees.

About Naturally Splendid Enterprises Ltd.

Naturally Splendid is a plant-based food manufacturing and technology company that produces and distributes nutritious and delicious plant-based commodity products. Founded in 2010, the Company operates a certified food manufacturing facility located just outside Vancouver, BC in Canada, focusing on producing an extensive range of plant-based entrees. Naturally Splendid has an exclusive 10-year manufacturing and distribution agreement for Canada with a division of Australia's largest plant-based food manufacturer, Flexitarian Foods Pty. Ltd.

In addition to producing the Company's own branded products, Naturally Splendid provides contract manufacturing services and private labelling for a variety of nutritional plant-based food products destined for multiple distribution channels. The Company launched PlanteinTM, a line of delicious plant-based meat alternatives for the rapidly growing plant-based market segment.

Naturally Splendid maintains a relationship Plasm Pharmaceutical, a company that has been approved for conducting a phase 2 clinical trial approved by Health Canada for the treatment of COVID-19.

NSE has also developed proprietary technologies for the extraction of healthy omega 3 and 6 oils, as well as a protein concentrate from hemp. For more information e-mail info@naturallysplendid.com or call Investor Relations at 604-570-0902 x 103

On Behalf of the Board of Directors

Mr. J. Craig Goodwin CEO, Director

Naturally Splendid Enterprises Ltd. (NSP - TSX Venture; NSPDF - OTCQB; 50N - Frankfurt) #108-19100 Airport Way Pitt Meadows, BC, V3Y 0E2 Office: (604) 570-0902 E-mail : info@naturallysplendid.com Website: www.naturallysplendid.com

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. Naturally Splendid cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond Naturally Splendid's control including, Naturally Splendid's ability to compete with large food and beverage companies; sales of any potential products developed will be profitable; sales of shelled hemp seed will continue at existing rates or increase; the ability to complete the sales of all bulk hemp seed purchase orders; and the risk that any of the potential applications may not receive all required regulatory or legal approval. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, Naturally Splendid undertakes no obligation to publicly update or revise forward-looking information.

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

SOURCE: Naturally Splendid Enterprises Ltd.

News Provided by ACCESSWIRE via QuoteMedia

Naturally Splendid Enterprises Ltd.("Naturally Splendid", "NSE" or "the Company") (FRANKFURT:50N) (TSXV:NSP) (OTC PINK:NSPDF) announces its unaudited financial results for the six months ended June 30, 2022. All amounts are in Canadian dollars and are prepared in accordance with International Financial Reporting Standards

Naturally Splendid CFO Mr. George Ragogna stated, "We are continuing to implement our plan focused on our plant-based opportunities, most notably PlanteinTM Plant-Based Foods. With most Covid restrictions now removed, we have been able to meet clients face to face at several trade shows after a multi-year hiatus, to promote the launch of our PlanteinTM retail line while developing national distribution and sales relationships. Responses from the trade shows have been overwhelmingly positive, resulting in multiple new accounts as well as building the foundation for many new business opportunities. The plant-based market is maturing, and consumers are demanding higher quality products, most notably beginning with taste. Feedback from these recent tradeshows has confirmed we have amongst the best tasting plant-based products available in the Canadian market, and demand for our PlanteinTM line continues to gain traction."

Strategic Focus on Manufacturing Plantein Plant-Based Foods

After careful consideration and discussions, the Naturally Splendid Enterprises management team, with support from the Board of Directors, has made a number of strategic decisions with the objective to prioritize the exclusive Canadian manufacturing and distribution opportunity of PlanteinTM Plant-Based Foods with Flexitarian Foods Pty. Ltd.

Since Naturally Splendid has partnered with Flexitarian Foods in an exclusive 10-year year manufacturing and distribution agreement for PlanteinTM for the Canadian market. The Company has also negotiated exclusive rights to the Plantein trademark for the same period. These exclusive agreements also have a 10-year renewal clause.

Outlook of the Plant-Based Market Opportunity

Today the retail market for plant-based foods is worth USD $10.9 billion with an expected Compound Annual Growth Rate (CAGR) of 12.2% (2022-2032). Furthermore, The National Research of Canada estimates that the protein demand will double to 943.5 million metric tons in 2054, and the opportunity for plant-based food is significant.

There are several reasons for the growing popularity of plant-based foods. The environmental sustainability of plant-based foods is a key factor as animal agriculture is a major contributor to greenhouse gas emissions, water consumption and deforestation. The UN reports that drought frequency and duration have increased by nearly a third globally since 2000. Plant-based foods require far less land and water than animal agriculture, generating fewer emissions.

Health concerns are another major factor driving the growth of the plant-based sector. Consumers are increasingly aware of the link between a plant-based diet and the reduction of chronic diseases such as heart disease, diabetes, and cancer.

Animal farming is also a key consideration for many people, as the factory farming of animals has come under increased scrutiny in recent years. Factory farming accounts for 37% of methane (CH4) emissions, which has more than 20 times the global warming potential of CO2. Plant-based agriculture uses an estimated 10% of the water required for animal farming and is far less damaging to the environment, driving even more environmentally concerned consumers to pursue a plant-based diet.

As the market for plant-based foods continues to grow, there is a tremendous opportunity for companies to provide products that meet consumer demand. Those that can supply healthy, sustainable, and delicious plant-based foods will be well-positioned to succeed in the coming years. Strategic Decisions Existing Operations

While focusing our resources on the PlanteinTM opportunity, all divisions, products and projects were reviewed thoroughly. The decisions on moving forward range from altering existing programs to suspending or eliminating certain projects and/or activities.

Bar manufacturing business including Elevate MeTM, NATERA, Woods WildTM, and contract manufacturing, are suspended while the facility undergoes expansion for the manufacturing of PlanteinTM plant-based products. Further plans are being developed and may include liquidating bars and bites assets or pursuing joint ventures or other business arrangements to manufacture and distribute bars and bites.

Prosnack Natural Foods will only focus on manufacturing PlanteinTM plant-based products under the Plantein brand, as well as for Private Label and Contract Manufacturing clients.

The Company has identified three (3) separate yet complimentary revenue streams generated from plant-based manufacturing:

PlanteinTM Brand - the Company will seek to list PlanteinTM branded products in both retail and foodservice outlets.

Private Label - the Company has access to over thirty (30) plant-based entrees created by Flexitarian Foods that will create significant private label opportunities.

Contract Manufacturing - In certain circumstances, Prosnack will manufacture for strategically selected contract manufacturing clients, producing their plant-based products in our facility.

The majority of the manufacturing equipment has been ordered, and various equipment has already arrived at our Pitt Meadows facility. We are experiencing delays in receiving certain manufacturing equipment due to supply challenges and ongoing logistics from Covid. During this time, the Company will continue to receive our plant-based inventories from Flexitarian Foods while we continue to work on completing our manufacturing lines at our own facility.

The Company will continue to progress with its Safe Quality Food (SQF) certification program, which will be completed upon the final commissioning of the new manufacturing lines. Although the facility was previously certified SQF2, the new plant-based production lines require an updated SQF plan to be developed and implemented.

We have also already sourced many of the ingredients required for manufacturing from Canadian suppliers. These ingredients have been evaluated with the oversight of Flexitarian Foods to confirm we are producing a product that replicates the flavour and texture profiles of the original recipes.

Sourcing ingredients locally is not only environmentally more sustainable but there are also significant savings associated with securing Canadian suppliers that directly contribute to bottom-line figures. The Company will see an almost immediate return by way of reducing production costs and improved inventory control, resulting in an anticipated increase in margins.

Naturally Splendid will no longer defend the NATERA brand name since we have secured the PlanteinTM trademark for Canada for our main priority, plant-based entrees. The Company is permitted to use the NATERA brand for certain bars and bites but will no longer seek the registered trademark.

Plasm Pharmaceutical Naturally Splendid has reached an agreement with Biologic to terminate the contract with Plasm Pharmaceutical and are negotiating a compensation package for all work done thus far for pursuing a potential treatment for Covid with the target drug Cavaltinib.

CHII Naturally Pure Hemp Operations remain as is focusing on online sales and bulk exports of hemp.

Pawsitive FX For the time being operations remain as is focusing on online sales of pet topicals. A further review will look to potentially sell this brand or consider other partnership-type scenarios.

Naturally Splendid recorded a net loss and comprehensive loss of $1,316,236 for the six months ended June 30, 2022, compared to a net loss of $1,403,685 during the six months ended June 30, 2021. Gross profit margins decreased by 2.6% of sales in the six months ended June 30, 2021, compared to the six months ended June 30, 2021. The Company's sales decreased by approximately $312,000 from the comparative period. During the six-month period ending June 30, 2022, selling and distribution expenses decreased by approximately $16,500, largely due to facility costs.

Administrative expenses for the six months ended June 30, 2022, decreased in 2022 compared to 2021 by $87,500. The decrease was primarily due to management & consulting fees, bank charges and legal fees.

Naturally Splendid recorded sales of $157,314 during the six months ended June 30, 2022, compared to $470,039 for the six months ended June 30, 2021. During the six months ended June 30, 2022, the Company's sales decreased by approximately $313,000 from the comparative period. The Company had decreased sales in its private-label bars and bites business by approximately $85,000. Branded hemp products decreased by approximately $170,200 and its Natera Sport products decreased by approximately $73,000. Sales in new Plant-based products decreased by approximately $4,300.

The Cost of Sales during the six months ended June 30, 2022, was $136,186 compared to $394,812 in 2021. The Company's sales were from its new line of plant-based entrees, which maintain a higher gross margin. The Company continues to focus on its higher-margin products and new commercial opportunities with its plant-based entrees.

About Naturally Splendid Enterprises Ltd.

Naturally Splendid is a plant-based food manufacturing and technology company that produces and distributes nutritious and delicious plant-based commodity products. Founded in 2010, the Company operates a certified food manufacturing facility located just outside Vancouver, BC in Canada, focusing on producing an extensive range of plant-based entrees. Naturally Splendid has an exclusive 10-year manufacturing and distribution agreement for Canada with a division of Australia's largest plant-based food manufacturer, Flexitarian Foods Pty. Ltd.

In addition to producing the Company's own branded products, Naturally Splendid provides contract manufacturing services and private labelling for a variety of nutritional plant-based food products destined for multiple distribution channels. The Company launched PlanteinTM, a line of delicious plant-based meat alternatives for the rapidly growing plant-based market segment.

Naturally Splendid maintains a relationship Plasm Pharmaceutical, a company that has been approved for conducting a phase 2 clinical trial approved by Health Canada for the treatment of COVID-19.

NSE has also developed proprietary technologies for the extraction of healthy omega 3 and 6 oils, as well as a protein concentrate from hemp. For more information e-mail info@naturallysplendid.com or call Investor Relations at 604-570-0902 x 103

On Behalf of the Board of Directors

Mr. J. Craig Goodwin CEO, Director

Naturally Splendid Enterprises Ltd. (NSP - TSX Venture; NSPDF - OTCQB; 50N - Frankfurt) #108-19100 Airport Way Pitt Meadows, BC, V3Y 0E2 Office: (604) 570-0902 E-mail : info@naturallysplendid.com Website: www.naturallysplendid.com

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. Naturally Splendid cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond Naturally Splendid's control including, Naturally Splendid's ability to compete with large food and beverage companies; sales of any potential products developed will be profitable; sales of shelled hemp seed will continue at existing rates or increase; the ability to complete the sales of all bulk hemp seed purchase orders; and the risk that any of the potential applications may not receive all required regulatory or legal approval. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, Naturally Splendid undertakes no obligation to publicly update or revise forward-looking information.

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

SOURCE: Naturally Splendid Enterprises Ltd.

News Provided by ACCESSWIRE via QuoteMedia

Not For Distribution to U.S. Newswire Services or for Release, Publication, Distribution, or Dissemination Directly, or Indirectly, in Whole or in Part, In or Into the United States

KWESST Micro Systems Inc. (TSXV: KWE) ("KWESST" or "the Company") today announced that it has closed two non-secured loans in the amount of USD$200,000 per loan with a third-party lender ("Lender") for an aggregate amount of USD$400,000 (the "Loans").

The Loans bear interest at a rate of 6.0% per annum, compounded monthly and not in advance, and have a maturity of twelve months, with the Company having the option to repay the whole or any part of the Loans, without penalty or premium, at any time prior to the close of business on the maturity date. On repayment of the Loans, KWESST shall pay 110% of the principal amount plus accrued interest on the Loan. As part of the terms of one of the Loans, KWESST issued an aggregate of 296,754 common shares to the Lender (the "Bonus Shares"), being an amount equal to twenty percent (20%) of USD$200,000, converted to CAD$ at an exchange rate of $1.2983, divided by the market price of the Company's common shares on the TSX Venture Exchange (the "Exchange") at market close on August 24, 2022, being CAD$0.175. The Bonus Shares were issued in accordance with applicable prospectus exemptions under Canadian securities laws.

Concurrently with the closing of the Loans, KWESST's Executive Chairman and its President and Chief Executive Officer (the "KWESST Principals") entered into call option agreements with the Lender whereby the Lender will have the option, pursuant to the terms and conditions of the call option agreements, to purchase 741,345 common shares held by the KWESST Principals at a price of CAD$0.175 for a period of five years. Additional free-trading common shares may be offered by the KWESST Principals to the Lender should KWESST elect to proceed with a share-for-debt transaction in connection with one of the Loans. KWESST is not a party to the call option agreements.

In connection with the Loans, KWESST agreed to pay a cash fee to ThinkEquity, a US based investment bank, and for certain of its expenses, in an aggregate amount of USD$37,000.

The securities issued in connection with the Loans are subject to a regulatory four-month and one day hold period expiring on December 26, 2022. The Loans remain subject to the final approval of the Exchange.

About KWESST KWESST (TSXV: KWE) (OTCQB: KWEMF) (FSE: 62U) commercializes breakthrough next-generation tactical systems for military and security forces and personal defense. The company's current portfolio of unique proprietary offerings includes non-lethal systems (PARA OPSTM and ARWENTM) with application across all segments of the non-lethal market, including law enforcement and personal defence. KWESST also facilitates digitization of tactical forces with its signature TASCS system for real-time awareness and targeting information from any source (including drones) streamed directly to users' smart devices and indirect fire weapons. Other KWESST products include countermeasures against threats such as drones, lasers and electronic detection. These include: the PhantomTM electronic battlefield deception system to mask the electromagnetic signature of friendly forces with decoy signatures at false locations that deceive and confuse adversaries; a Battlefield Laser Detection System to counter the emerging threat of laser targeting of personnel; and, a non-kinetic system to counter the threat of tactical drones. These systems can operate stand-alone or integrate seamlessly with third-party OEM products and networked battlefield management systems such as ATAK. The Company is headquartered in Ottawa, Canada, with operations in Stafford, VA and representative offices in London, UK and Abu Dhabi, UAE.

For more information, please visit https://kwesst.com/.

Contact: Steve Archambault, CFO, archambault@kwesst.com or (613) 317-3941 Jason Frame, Investor Relations: frame@kwesst.com

Investor Contact: Dave Gentry, CEO RedChip Companies 1-800 RED-CHIP (733-2447) 407-491-4499 KWEMF@redchip.com

Press Contact: Angela Trostle Gorman angela@AMWPR.com 1-917-348-0083

Cautionary Note Regarding Forward-Looking Statements Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates" and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/135213

News Provided by Newsfile via QuoteMedia

Investing News Network websites or approved third-party tools use cookies. Please refer to the  cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.